NCT06237920 - Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

August 1, 2028

Conditions

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesMale Urogenital DiseasesUrinary Bladder NeoplasmAntineoplastics Toxicity

Interventions

DRUG

Nivolumab

Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.

DRUG

Relatlimab

Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.

Trial Locations (9)

6815AD

NOT_YET_RECRUITING

Rijnstate, Arnhem

6525GA

RECRUITING

Radboud University Medical Center, Nijmegen

1066CX

RECRUITING

NKI-AVL, Amsterdam

1081HV

RECRUITING

Amsterdam UMC (AUMC), Amsterdam

2143TM

RECRUITING

Spaarne Gasthuis, Hoofddorp

8025AB

NOT_YET_RECRUITING

ISALA, Zwolle

2333ZA

RECRUITING

Leiden University Medical Center (LUMC), Leiden

3015GD

RECRUITING

Erasmus Medical Center, Rotterdam

3584CX

RECRUITING

University Medical Center Utrecht, Utrecht